A pivotal hit in allergic conjunctivitis could also bode well for upcoming readouts in the bigger indication of dry eye disease.
NOV03 posts a pivotal win but the late-stage dry eye pipeline is crowded.
Key catalysts approach for Orphazyme, Gemini and Immutep.
The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.
Pivotal data validate Aldeyra’s lead project, reproxalap, but there are questions about a lack of dose response.
Two readouts are approaching for Axsome's AXS-05, and Aldeyra is facing a data-heavy 2019.
After failing in retinal vein occlusion, the prospects for the eye project Xipere – and Clearside Biomedical itself – hinge on the smaller uveitis indication.